In DLBCL but not in WM, the MYD88 L265P mutation frequently co-occurs with mutations in CD79B, an essential BCR complex-associated protein, suggesting that BCR and TLR signaling cooperate to optimally promote NF-kB signaling and tumor cell survival [2, 3, 8]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.